logo-loader
viewPharmaxis Ltd

Pharmaxis strengthens board through appointment of Dr Neil Graham

The new US-based non-executive director is an experienced senior global pharma and biotech executive.

Pharmaxis Ltd - Pharmaxis strengthens board through appointment of Dr Neil Graham
Dr Graham has had a distinguished academic and business career

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) has strengthened its board through the appointment of experienced senior global pharma and biotech executive Dr Neil Graham as a non-executive director.

The new US-based director, who will take up the role today, is a medicines development expert and infectious diseases epidemiologist who has had a distinguished academic and business career.

“Relevant to development assets”

Pharmaxis chairman Malcolm McComas said: “We are delighted to welcome Neil to the Pharmaxis Board.

“His global career in drug development is directly relevant to our current development assets such as the systemic pan-LOX inhibitor that will move into phase 2 studies later this year.

“We look forward to Neil’s involvement in our clinical programs and strategic partnerships.”

Role at Regeneron

Dr Graham recently retired as vice-president of Strategic Program Direction at Regeneron Pharmaceuticals Inc (NASDAQ:REGN) where he was responsible for the pipeline portfolio.

In this role, he successfully led development of immunology and inflammation products from preclinical development to post-launch.

Between 2007 and 2009 he was senior vice-president, Program and Portfolio Management at Vertex, Cambridge, USA, overseeing all development programs including studies in cystic fibrosis and inflammation.

Evelo chief development officer

He has previously led clinical development programs as a senior executive at Trimeris Inc and XTL Biopharmaceuticals and also recently joined Evelo Biosciences Inc (NASDAQ:EVLO) as chief development officer.

Dr Graham was educated at University of Adelaide (MBBS, MD, MPH). Between 1993 and 1997 he was Associate Professor of Epidemiology at John Hopkins University School of Hygiene and Public Health with research focused on HIV, tuberculosis and hepatitis.

He has authored a number of books and publications including a considerable body of work on respiratory illness.

Quick facts: Pharmaxis Ltd

Price: 0.094 AUD

ASX:PXS
Market: ASX
Market Cap: $37.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read